New trial
Phase II Trial of HLX43 (Anti-PD-L1 ADC) in Advanced NSCLC
- Trial ID
- NCT06907615 on ClinicalTrials.gov
- Cancer type
- Non-Small Cell Lung Cancer (NSCLC)
- Location
- 2 Locations
- Published in
- New in Oncology - May 21, 2025
Henlius is launching a global, open-label Phase II study to explore the optimal dosing and evaluate the efficacy, safety, and tolerability of HLX43 in patients with advanced/metastatic NSCLC, including those with EGFR mutations.
More on NCT06907615
-
Trial result · Jun 11, 2026
HLX43 (anti–PD-L1 ADC) drives 31% ORR in heavily pretreated NSCLC—PD-L1–independent activity
More in non-small cell lung cancer
-
Trial result · Oct 22, 2026 · NCT04905316
Canakinumab (IL-1β blockade) + cCRT and durvalumab consolidation hits 67% 24-mo PFS in unresectable stage III NSCLC -
Trial result · Oct 15, 2026 · NCT04495153
CAN-2409 + valacyclovir reports 14.3-month median OS in treated NSCLC patients; 24.5 months in a selected per-protocol group -
New trial · Oct 15, 2026 · NCT07852247
Phase 1 CyberKnife SBRT uses Synchrony respiratory motion tracking for ultra-central NSCLC -
New trial · Oct 15, 2026 · NCT07617337
Phase 1 AQUA07 allosteric ALK inhibitor (macrocyclic peptide) alone or with lorlatinib in ALK-positive NSCLC -
Trial result · Oct 8, 2026 · NCT03052608
AI volumetric brain-met response may better predict PFS in ALK+ NSCLC